U.S. Court in California Allows FCA Action Alleging Lab Improperly Induced Physicians to Order Tests
- May 29, 2020
The U.S. District Court for the Northern District of California refused to dismiss whistleblower claims May 23, finding the lab testing schemes alleged against defendants Crescendo Bioscience, Inc. and Myriad Genetics, Inc. were sufficiently detailed at this stage of the litigation.
ARTICLE TAGS
You must be logged in to access this content.